2017
DOI: 10.1016/j.jval.2017.08.2579
|View full text |Cite
|
Sign up to set email alerts
|

Cost Per Response Analysis of Nivolumab Versus Everolimus in the Treatment of Patients Previously Treated with Advanced Renal Cell Carcinoma – Brazil Private Health Care System Perspective

Abstract: A875substantially higher objective response rates favouring patients receiving nivolumab (25.1% vs 5.4%; odds ratio: 5.98, P< 0.001) was observed in this trial. The aim of this analysis was to compare the monthly cost per responder with nivolumab versus everolimus in the Brazilian private healthcare system perspective. Methods: This analysis was based on investigator-based patient-level data from a randomized phase III trial. ORR was defined as the proportion of patients who achieved a partial or complete resp… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2020
2020
2021
2021

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…Favorable evidence for high-value drugs could incentivize the development of novel drug regimens and facilitate conversations in clinical practice. To facilitate value-driven decision-making, an evolving field from the perspective of stakeholders-physicians, patients, health care insurers, etc., including the American Society of Clinical Oncology (ASCO) (Schnipper et al, 2015;Schnipper et al, 2016) and the European Society for Medical Oncology (ESMO) (Cherny et al, 2015;Cherny et al, 2017) have independently proposed frameworks as unbiased tools for systematic assessment of value of anticancer drugs, justifiably evaluating high quality therapies affordable for various cancer disease states.…”
Section: Introductionmentioning
confidence: 99%
“…Favorable evidence for high-value drugs could incentivize the development of novel drug regimens and facilitate conversations in clinical practice. To facilitate value-driven decision-making, an evolving field from the perspective of stakeholders-physicians, patients, health care insurers, etc., including the American Society of Clinical Oncology (ASCO) (Schnipper et al, 2015;Schnipper et al, 2016) and the European Society for Medical Oncology (ESMO) (Cherny et al, 2015;Cherny et al, 2017) have independently proposed frameworks as unbiased tools for systematic assessment of value of anticancer drugs, justifiably evaluating high quality therapies affordable for various cancer disease states.…”
Section: Introductionmentioning
confidence: 99%
“…A study conducted from the Brazilian private healthcare system perspective calculated a monthly average adverse event costs per patient for nivolumab of 199.83 BRL, representing only 0.5% of total treatment costs 46 . The available data suggest that adverse event management costs may not significantly impact the conclusion.…”
Section: Discussionmentioning
confidence: 99%